Molecular plasticity of LAMA3 across the disease spectrum: pathogenic mechanisms and clinical translation.

Clinical Snapshot

Key Findings

• P Value: Not reported

• Effect Size: Not reported — no pooled quantitative effect sizes provided; LAMA3 described as an independent prognostic indicator in pancreatic ductal adenocarcinoma without accompanying hazard ratios or odds ratios in the abstract

• Primary Outcome: LAMA3 functions as an oncogenic determinant in colorectal and ovarian cancers (enhancing invasion, metastasis, and chemoresistance) while serving as a structural deficiency determinant in junctional epidermolysis bullosa and idiopathic pulmonary fibrosis

• Nnt Or Sensitivity: Not applicable — no NNT, sensitivity, specificity, or hazard ratio data are synthesised quantitatively in this review

• Confidence Interval: Not reported

Clinical Application

Direct clinical application is currently limited. LAMA3 promoter methylation testing as a biomarker for platinum resistance in ovarian cancer is conceptually feasible but requires prospective validation. Gene therapy for JEB is in clinical evaluation but not yet standard of care. PROTAC-based LAMA3 targeting remains preclinical. Colorectal cancer is the second most common cancer in Australia (Cancer Australia data), making LAMA3 prognostic biomarker research potentially relevant to Australian oncology practice. Ovarian cancer platinum resistance is a significant clinical challenge managed within Australian gynaecological oncology networks. JEB is managed through specialist dermatology and genetics services; gene therapy trials are not currently available through the TGA or PBS. IPF management in Australia follows RACGP and Thoracic Society of Australia and New Zealand guidelines, with antifibrotic agents (nintedanib, pirfenidone) PBS-listed; LAMA3-targeted approaches are not yet clinically available. No TGA-approved LAMA3-directed therapeutics currently exist. Patients with LAMA3-overexpressing malignancies (colorectal, ovarian, pancreatic cancers), patients with junctional epidermolysis bullosa due to LAMA3 loss-of-function variants, and patients with idiopathic pulmonary fibrosis with LAMA3 dysregulation

Abstract

The laminin α3 chain, encoded by LAMA3, constitutes a principal component of laminin-332 (LN-332), an essential extracellular matrix (ECM) glycoprotein governing cell adhesion, proliferation, and tissue homeostasis. This systematic review consolidates current evidence on the molecular features and regulatory mechanisms of LAMA3, including its roles in PI3K/Akt, epithelial-mesenchymal transition (EMT), and Hippo-YAP signaling, as well as epigenetic and post-transcriptional modulation. Its context-dependent functions across distinct pathological states are delineated. In malignancies, including colorectal and ovarian cancers, LAMA3 functions as an oncogenic determinant that enhances invasion, metastatic dissemination, and chemotherapeutic resistance. In contrast, in hereditary diseases such as junctional epidermolysis bullosa (JEB) and chronic disorders such as idiopathic pulmonary fibrosis (IPF), LAMA3 deficiency or dysfunction constitutes a structural basis of tissue pathology. From a translational standpoint, elevated LAMA3 expression has been recognized as an independent prognostic indicator in pancreatic ductal adenocarcinoma, whereas LAMA3 promoter methylation is a candidate biomarker for platinum resistance in ovarian cancer. LAMA3-directed gene therapy for JEB has progressed to clinical evaluation. Current limitations in the field are critically examined, and emerging therapeutic approaches, including proteolysis-targeting chimeras (PROTACs), are discussed. Collectively, an integrated framework that connects LAMA3 biology with clinical applications is presented to inform future investigations and precision therapeutic strategies targeting this multifunctional molecule.

References

1. 1.Luo, C., Qin, F., Bao, M., Yao, D., & Qin, M. (2026). Molecular plasticity of LAMA3 across the disease spectrum: pathogenic mechanisms and clinical translation. Histochemistry and Cell Biology. https://doi.org/10.1016/j.xhgg.2023.100227 [Note: DOI prefix inconsistency flagged — verify against publisher record prior to citation]